Study why PSMA radioligand therapy stops working
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study looks at tissue samples from tumors to understand how and why PSMA radioligand therapy may become less effective. If you have PSMA-avid cancer lesions that can be biopsied, the trial may help researchers find ways to improve treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are starting a PSMA-targeted radioligand treatment using lutetium
- You have a PSMA-avid tumor spot that a doctor can safely biopsy
- If you take blood thinners, you must be able to stop them for at least 5 days before the biopsy
- You are 18 years or older and can sign informed consent
- You must be able to have extra study scans (extra imaging)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This trial studies blood tests (liquid biopsies) in men with metastatic prostate cancer that no longer responds to hormone therapy or chemotherapy and who are receiving a type of radiation therapy called PSMA RLT. The goal is to see if these blood tests can provide useful information about the cancer and treatment response.
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.